Clinical Trials
171 trialsA Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Grupo Espanol de Tumores Neuroendocrinos
LuPARP
Vastra Gotaland Region
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
M.D. Anderson Cancer Center
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
ArTisaN
Imperial College London
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
MGMT-NET
Hospices Civils de Lyon
Open-label Study of Surufatinib in Japanese Patients
Hutchmed
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Ariceum Therapeutics GmbH
TALENT
Grupo Espanol de Tumores Neuroendocrinos
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
Azienda USL Reggio Emilia - IRCCS
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Nuvation Bio Inc.
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
ARROW
Hoffmann-La Roche
SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
Jewish General Hospital
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Memorial Sloan Kettering Cancer Center
FETONET
Imperial College London
GENEBIOLuNET
University Hospital, Toulouse
18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies
Memorial Sloan Kettering Cancer Center
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Clarity Pharmaceuticals Ltd
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
Novartis
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Dual-Tracer Theranostic PET
University of Utah
Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
Latin American Cooperative Oncology Group
Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Advanced Accelerator Applications
LuX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
University of Michigan Rogel Cancer Center
DUNE
Grupo Espanol de Tumores Neuroendocrinos
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
Abramson Cancer Center at Penn Medicine
Liquid-NET
Universiteit Antwerpen
NET-002
Sunnybrook Health Sciences Centre
Phase 2 Study of ONC201 in Neuroendocrine Tumors
Case Comprehensive Cancer Center
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
PALACE
Ipsen
EVACEL
Federation Francophone de Cancerologie Digestive
Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients
Yonsei University
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Olivia Newton-John Cancer Research Institute
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
Jonsson Comprehensive Cancer Center
DIB-NET
University Hospitals Coventry and Warwickshire NHS Trust
WIN
University Medical Center Groningen
WIN
University Medical Center Groningen
DIVIT-pilot
University Medical Center Groningen